67294 Federal Register / Vol. 88, No. 188 / Friday, September 29, 2023 / Notices 

EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN—Continued 

Form name Number of 

respondents 

Total 

burden 

hours 

Average 

hourly wage 

rate 

Total cost 

burden 

Office-based Providers Event Form ................................................................................ 14,950 3,214 ** 19.84 63,766 

Separately Billing Doctors (SBD) Event Form ................................................................ 12,690 888 ** 19.84 17,618 

Hospitals & HMOs (Hospital Event Form ........................................................................ 8,302 3,113 ** 19.84 61,762 

Institutions (non-hospital) Event Form ............................................................................. 118 8 ** 19.84 159 

Pharmacies Event Form .................................................................................................. 9,079 17,068 *** 19.35 330,266 

Subtotal for the MEPS–MPC ........................................................................................... 100,783 29,111 .................... 569,200 

Grand Total ............................................................................................................... 142,383 77,067 .................... 1,979,436 

* Mean hourly wage for All Occupations (00–0000). 

** Mean hourly wage for Medical Secretaries (43–6013). 

*** Mean hourly wage for Pharmacy Technicians (29–2052). 

Occupational Employment Statistics, May 2022 National Occupational Employment and Wage Estimates United States, U.S. Department of 

Labor, Bureau of Labor Statistics. 

Request for Comments 

In accordance with the Paperwork 

Reduction Act, 44 U.S.C. 3501–3520, 

comments on AHRQ’s information 

collection are requested with regard to 

any of the following: (a) whether the 

proposed collection of information is 

necessary for the proper performance of 

AHRQ’s health care research and health 

care information dissemination 

functions, including whether the 

information will have practical utility; 

(b) the accuracy of AHRQ’s estimate of 

burden (including hours and costs) of 

the proposed collection(s) of 

information; (c) ways to enhance the 

quality, utility and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information upon the 

respondents, including the use of 

automated collection techniques or 

other forms of information technology. 

Comments submitted in response to 

this notice will be summarized and 

included in the Agency’s subsequent 

request for OMB approval of the 

proposed information collection. All 

comments will become a matter of 

public record. 

Dated: September 26, 2023. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2023–21473 Filed 9–28–23; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Supplemental Evidence and Data 

Request on Healthcare Industry Waste 

and Lifecycle Assessment 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Request for supplemental 

evidence and data submissions. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) is seeking 

scientific information submissions from 

the public. Scientific information is 

being solicited to inform our review on 

Healthcare Industry Waste and Lifecycle 

Assessment, which is currently being 

conducted by the AHRQ’s Evidencebased Practice Centers (EPC) Program. 

Access to published and unpublished 

pertinent scientific information will 

improve the quality of this review. 

DATES: Submission Deadline on or 

before October 30, 2023. 

ADDRESSES:

Email submissions: epc@

ahrq.hhs.gov. 

Print submissions: 

Mailing Address: Center for Evidence 

and Practice Improvement, Agency for 

Healthcare Research and Quality, 

ATTN: EPC SEADs Coordinator, 5600 

Fishers Lane, Mail Stop 06E53A, 

Rockville, MD 20857. 

Shipping Address (FedEx, UPS, etc.): 

Center for Evidence and Practice 

Improvement, Agency for Healthcare 

Research and Quality, ATTN: EPC 

SEADs Coordinator, 5600 Fishers Lane, 

Mail Stop 06E77D, Rockville, MD 

20857. 

FOR FURTHER INFORMATION CONTACT: 

Kelly Carper, Telephone: 301–427–1656 

or Email: epc@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Agency for Healthcare Research and 

Quality has commissioned the 

Evidence-based Practice Centers (EPC) 

Program to complete a review of the 

evidence for Healthcare Industry Waste 

and Lifecycle Assessment. AHRQ is 

conducting this review pursuant to 

section 902 of the Public Health Service 

Act, 42 U.S.C. 299a. 

The EPC Program is dedicated to 

identifying as many studies as possible 

that are relevant to the questions for 

each of its reviews. In order to do so, we 

are supplementing the usual manual 

and electronic database searches of the 

literature by requesting information 

from the public (e.g., details of studies 

conducted). We are looking for studies 

that report on Healthcare Industry 

Waste and Lifecycle Assessment. The 

entire research protocol is available 

online at: https://effectivehealthcare.

ahrq.gov/products/lifecycle-assessment. 

This is to notify the public that the 

EPC Program would find the following 

information on Healthcare Industry 

Waste and Lifecycle Assessment helpful: 

D A list of completed studies that 

your organization has sponsored for this 

topic. In the list, please indicate 

whether results are available on 

ClinicalTrials.gov along with the 

ClinicalTrials.gov trial number. 

D For completed studies that do not 

have results on ClinicalTrials.gov, a 

summary, including the following 

elements, if relevant: study number, 

study period, design, methodology, 

indication and diagnosis, proper use 

instructions, inclusion and exclusion 

criteria, primary and secondary 

outcomes, baseline characteristics, 

number of patients screened/eligible/ 

enrolled/lost to follow-up/withdrawn/ 

analyzed, effectiveness/efficacy, and 

safety results. 

D A list of ongoing studies that your 

organization has sponsored for this 

topic. In the list, please provide the 

ClinicalTrials.gov trial number or, if the 

trial is not registered, the protocol for 

the study including, if relevant, a study 

number, the study period, design, 

methodology, indication and diagnosis, 

proper use instructions, inclusion and 

exclusion criteria, and primary and 

secondary outcomes. 

D Description of whether the above 

studies constitute ALL Phase II and 

above clinical trials sponsored by your 

organization for this topic and an index 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 188 / Friday, September 29, 2023 / Notices 67295 

outlining the relevant information in 

each submitted file. 

Your contribution is very beneficial to 

the Program. Materials submitted must 

be publicly available or able to be made 

public. Materials that are considered 

confidential; marketing materials; study 

types not included in the review; or 

information on topics not included in 

the review cannot be used by the EPC 

Program. This is a voluntary request for 

information, and all costs for complying 

with this request must be borne by the 

submitter. 

The draft of this review will be posted 

on AHRQ’s EPC Program website and 

available for public comment for a 

period of 4 weeks. If you would like to 

be notified when the draft is posted, 

please sign up for the email list at: 

https://www.effectivehealthcare.

ahrq.gov/email-updates. 

The review will answer the following 

questions. This information is provided 

as background. AHRQ is not requesting 

that the public provide answers to these 

questions. 

Guiding Questions (GQ) 

GQ1. Frameworks for Life Cycle 

Assessment (LCA) 

• What LCA frameworks have been 

developed or adapted for healthcare 

settings, products, and procedures? 

i. What data sources, measures/ 

indicators, and methods are used to 

inform these frameworks? 

ii. Which components of the 

frameworks are thought to have the 

greatest association with carbon 

footprint? 

iii. What limitations of these 

frameworks have been described? 

GQ2. Studies of LCA 

• How are LCAs applied in healthcare 

research? 

i. What topic areas have been studied 

and for what settings? 

ii. What data sources, measures/ 

indicators, and methods were used in 

the analysis? 

iii. What outcomes have been studied, 

and what were the findings? 

iv. What were cited limitations of the 

research? 

GQ3. Gaps in the Knowledge and Future 

Research Needs 

• Are there frameworks that are being 

developed or have been developed but 

not yet implemented? 

• What are possible areas of future 

research? 

CRITERIA FOR INCLUSION/EXCLUSION OF STUDIES IN THE REVIEW

Domain Inclusion Exclusion 

Population ........ • GQ1: Publications that include a figure or detailed description of a life cycle assessment framework.

• GQ2: Publications that describe the methods and results of 

a life cycle assessment study.

• GQ3: Registered research of life cycle framework development or assessment.

• Publications citing existing frameworks without further conceptual contribution to the framework and publications describing only the need or future plans of conducting a life 

cycle assessment. 

Concept ............ Life cycle assessments that address either scope 1, scope 2, 

scope 3 emissions. Scope 1: Direct emissions (facilities, 

anesthetics, fleet and leased vehicles), Scope 2: Indirect 

emissions (electricity, stream). Scope 3: Other indirect 

emissions (food and catering, business services, medical 

devices, medicines, water, metered-dose inhalers, energy 

[well-to-tank], business travel [public transit, gray fleet], 

staff commuting, manufacturing [products, chemicals, 

gases], waste, information technology, Health Care Organization (HCO) investments, construction, and freight transport).

• GQ1: Frameworks for life cycle assessments, including 

logic models, analytic frameworks, or other 

conceptualization.

• GQ2: Published life cycle assessments, life cycle assessments do not need to meet ISO (International Organization 

for Standardization) 14040 standards but need to describe 

a goal, scope, and boundaries; assessment can describe 

partials or full cradle to grave cycles.

• GQ3: Ongoing research, development of frameworks and 

assessments.

• Frameworks, assessments, ongoing research not including 

life cycle assessments. 

Context ............. • Healthcare: healthcare delivery organizations, health insurance, or manufacturers/suppliers that directly contribute to 

the delivery of healthcare (e.g., supply of personal protective equipment) including scope 1, scope 2, and scope 3 

emissions.

• Studies in contexts not specific to healthcare. 

Other limiter ...... • Information published in English-language journal manuscripts, trial records, and gray literature in the public domain from the outlined sources.• Data reported in abbreviated format (e.g., conference abstracts) will be excluded; systematic reviews will be retained for reference mining. 

Abbreviations: GQ guiding questions; 

HCO health care organization; ISO 

International Standards Organization. 

Dated: September 26, 2023. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2023–21481 Filed 9–28–23; 8:45 am] 

BILLING CODE 4160–90–P 


lotter on DSK11XQN23PROD with NOTICES1